No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
MIXE Sensitive: A2 - Guideline
|
MIXE Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
TPF Sensitive: A2 - Guideline
|
TPF Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
FOLFCIS Sensitive: A2 - Guideline
|
FOLFCIS Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
mFOLFOX6 Sensitive: A2 - Guideline
|
mFOLFOX6 Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
DCF Sensitive: A2 - Guideline
|
DCF Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
cisplatin + carboplatin Sensitive: A2 - Guideline
|
cisplatin + carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Anal Carcinoma
|
No biomarker
|
Anal Carcinoma
|
cisplatin + 5-fluorouracil + capecitabine Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil + capecitabine Sensitive: A2 - Guideline
|
PD-L1 expression
|
Anal Carcinoma
|
PD-L1 expression
|
Anal Carcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 overexpression + TMB-H
|
Anal Carcinoma
|
PD-L1 overexpression + TMB-H
|
Anal Carcinoma
|
EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials
|
EGFR inhibitor + Immunotherapy Sensitive: C3 – Early Trials
|
CD163 expression
|
Anal Carcinoma
|
CD163 expression
|
Anal Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
CD4 expression
|
Anal Carcinoma
|
CD4 expression
|
Anal Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Anal Carcinoma
|
PD-L1 expression
|
Anal Carcinoma
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
PD-L1 amplification + PD-L2 amplification + TMB-H
|
Anal Carcinoma
|
PD-L1 amplification + PD-L2 amplification + TMB-H
|
Anal Carcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|